首页 | 本学科首页   官方微博 | 高级检索  
     


Multimodal molecular imaging in drug discovery and development
Affiliation:1. The Maastricht MultiModal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands;2. Development Science, UCB Biopharma SRL, Chemin du Foriest, B1420 Braine-l’Alleud, Belgium;3. DMPK, UCB Celltech, Branch of UCB Pharma SA, 208 Bath Road, Slough SL1 3WE, UK
Abstract:In addition to individual imaging techniques, the combination and integration of several imaging techniques, so-called multimodal imaging, can provide large amounts of anatomical, functional, and molecular information accelerating drug discovery and development processes. Imaging technologies aid in understanding the disease mechanism, finding new pharmacological targets, and assessment of new potential drug candidates and treatment response. Here, we describe how different imaging techniques can be used in different phases of drug discovery and development and highlight their strengths, related innovations, and future potential with a focus on the implementation of artificial intelligence (AI) and radiomics for imaging technologies.
Keywords:Multimodal imaging  Molecular imaging  Artificial intelligence  Radiomics  Preclinical research
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号